Alzheimer's Trials: Replacing Reams Of Paper For LAR Consent

By Cal Collins

Alzheimer’s disease (AD) is a growing global challenge, with cases expected to reach 152 million by 2060. With over 3,300 AD clinical trials currently in progress, managing informed consent for participants with cognitive impairment presents a significant challenge. When individuals can no longer provide consent, a Legally Authorized Representative (LAR)—such as a spouse, guardian, or healthcare proxy—must do so on their behalf. Additionally, LARs often participate in study-related assessments on separate schedules, adding complexity to trial management. Relying on paper-based workflows for these processes increases administrative burden, risks data inconsistencies, and complicates regulatory compliance.

OpenClinica’s automated LAR workflow streamlines this process by digitally linking participant and LAR records while keeping them distinct. This structured solution ensures that consent, reconsent, and assessments are accurately documented and compliant with regulations. The eConsent matrix provides researchers with clear visibility into participant and study partner statuses, reducing administrative strain.